Adagio Medical Treats First Patient with Next-Gen ULTA System — Adagio Medical Holdings, Inc.

Event summary

Adagio Medical successfully treated the first patient with its next-generation vCLAS Ultra system under FDA Expanded Access authorization.
The patient, with non-ischemic cardiomyopathy and failed prior ablations, was treated at the Hospital of University of Pennsylvania by Dr. Gregory Supple.
The vCLAS Ultra system aims to reduce ablation time by 50-75% compared to the first-generation system.
FDA has granted IDE approval to expand the FULCRUM-VT trial to evaluate the next-generation vCLAS Ultra System for treating Sustained Monomorphic Ventricular Tachycardia (SMVT).
Adagio's ULTA technology demonstrated a 2.4% major adverse events rate and 84% freedom from ICD shock at six months in the FULCRUM-VT study.

The big picture

Adagio Medical's next-generation vCLAS Ultra system represents a significant advancement in catheter ablation technology for treating ventricular tachycardia (VT). The successful treatment of the first patient underscores the potential of ULTA technology to address unmet needs in both ischemic and non-ischemic cardiomyopathy patients. This milestone comes as Adagio prepares for FDA approval of its first-generation ULTA system, positioning the company at the forefront of innovative solutions for cardiac arrhythmias.

What we're watching

Regulatory Approval: Whether the FDA approval of Adagio's first-generation ULTA system will be expedited given the successful initial use of the next-generation vCLAS Ultra system.
Clinical Efficacy: How the pre-clinical data on ablation time reduction and procedure efficiency translates into real-world clinical outcomes.
Market Adoption: The pace at which electrophysiologists adopt the vCLAS Ultra system for treating complex VT cases, particularly those involving thick myocardium and proximity to critical structures.